Informações de Merck & Co Inc | Histórico, dados financeiros e desempenho de mercado

Informações de Merck & Co Inc Empresa

Merck & Co., Inc. is a research-intensive biopharmaceutical company engaged in research to deliver health solutions that advance the prevention and treatment of diseases in people and animals. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. Human health vaccine products consist of preventive pediatric, adolescent and adult vaccines. The Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all major livestock and companion animal species. It is also engaged in developed a novel class of small molecules that target cancer cells lacking expression of a key DNA repair protein called O6-methylguanine methyl transferase.

Informações da empresa

Código da empresaMRK

Nome da EmpresaMerck & Co Inc

Data de listagemJan 01, 1941

Fundado em1970

CEOMr. Robert M. (Rob) Davis

Funcionários75000

Tipo de TítulosOrdinary Share

Fim do ano fiscalJan 01

Endereço2000 Galloping Hill Road

CidadeKENILWORTH

Bolsa de ValoresNYSE Consolidated

PaísUnited States of America

Código postal07033

Telefone19087404000

Sitehttps://www.merck.com/

Código da empresaMRK

Data de listagemJan 01, 1941

Fundado em1970

Executivos da Empresa

Nome

Nome/Posição

Posição

Ações Detidas

Variação

Mr. Robert M. (Rob) Davis

Chairman of the Board, President, Chief Executive Officer

443.60K

+27.35%

Mr. Sanat Chattopadhyay

Executive Vice President and President - Merck Manufacturing Division

185.33K

+17.90%

Dr. Dean Y. Li, M.D., Ph.D.

Executive Vice President, President - Merck Research Laboratories

78.86K

+70.54%

Ms. Caroline Litchfield

Chief Financial Officer, Executive Vice President

74.34K

+46.03%

Mr. Chirfi Guindo

Senior Vice President, Chief Marketing Officer - Human Health

66.61K

+73.22%

Ms. Jennifer L. Zachary

Executive Vice President, General Counsel, Corporate Secretary

53.42K

+90.81%

Mr. Michael A. Klobuchar

Executive Vice President, Chief Strategy Officer

23.22K

+1.98%

Mr. Joseph Edward Romanelli

Senior Vice President, President - MSD International Human Health

20.72K

+5.86%

Ms. Patricia F. Russo

Independent Director

13.15K

--

Mr. Thomas Henry (Tom) Glocer, J.D.

Lead Independent Director

5.10K

--

Ver Mais

Nome

Nome/Posição

Posição

Ações Detidas

Variação

Mr. Robert M. (Rob) Davis

Chairman of the Board, President, Chief Executive Officer

443.60K

+27.35%

Mr. Sanat Chattopadhyay

Executive Vice President and President - Merck Manufacturing Division

185.33K

+17.90%

Dr. Dean Y. Li, M.D., Ph.D.

Executive Vice President, President - Merck Research Laboratories

78.86K

+70.54%

Ms. Caroline Litchfield

Chief Financial Officer, Executive Vice President

74.34K

+46.03%

Mr. Chirfi Guindo

Senior Vice President, Chief Marketing Officer - Human Health

66.61K

+73.22%

Ms. Jennifer L. Zachary

Executive Vice President, General Counsel, Corporate Secretary

53.42K

+90.81%

Detalhamento da Receita

Moeda: USDTempo de atualização: há 22 horas

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

Por EmpresaUSD

Nome

Receita

Proporção

Oncology-Keytruda

29.48B

45.95%

Vaccines -Gardasil/Gardasil

8.58B

13.38%

Animal Health-Livestock

3.46B

5.39%

Other pharmaceutical

2.51B

3.91%

Vaccines -ProQuad/M-M-R II/Varivax

2.48B

3.87%

Other

17.65B

27.50%

Por RegiãoUSD

Nome

Receita

Proporção

United States

32.28B

50.30%

Europe, Middle East and Africa

14.04B

21.88%

China

5.49B

8.56%

Latin America

3.46B

5.39%

Japan

3.28B

5.11%

Other

5.62B

8.75%

Por Empresa

Por Região

Por EmpresaUSD

Nome

Receita

Proporção

Oncology-Keytruda

29.48B

45.95%

Vaccines -Gardasil/Gardasil

8.58B

13.38%

Animal Health-Livestock

3.46B

5.39%

Other pharmaceutical

2.51B

3.91%

Vaccines -ProQuad/M-M-R II/Varivax

2.48B

3.87%

Other

17.65B

27.50%

Acionista

Tempo de atualização: ter, 11 de mar

Estatísticas do Acionista

Tipo

Estatísticas do Acionista

Acionista

Proporção

The Vanguard Group, Inc.

10.03%

BlackRock Institutional Trust Company, N.A.

5.68%

State Street Global Advisors (US)

4.79%

Wellington Management Company, LLP

3.20%

Geode Capital Management, L.L.C.

2.42%

Other

73.89%

Estatísticas do Acionista

Acionista

Proporção

The Vanguard Group, Inc.

10.03%

BlackRock Institutional Trust Company, N.A.

5.68%

State Street Global Advisors (US)

4.79%

Wellington Management Company, LLP

3.20%

Geode Capital Management, L.L.C.

2.42%

Other

73.89%

Tipo

Acionista

Proporção

Investment Advisor/Hedge Fund

35.88%

Investment Advisor

31.49%

Research Firm

3.76%

Pension Fund

2.96%

Bank and Trust

2.38%

Hedge Fund

1.52%

Sovereign Wealth Fund

1.49%

Insurance Company

0.69%

Family Office

0.11%

Other

19.72%

Instituição Participações

Tempo de atualização: qui, 20 de fev

Período do Relatório

Nº de instituições

Ações detidas

Proporção

Variação

2025Q1

5308

2.05B

81.06%

+16.18M

2024Q4

5410

2.04B

80.88%

+11.87M

2024Q3

5200

2.01B

79.47%

-7.96M

2024Q2

5181

2.01B

79.28%

-4.86M

2024Q1

5154

2.00B

78.88%

-6.10M

2023Q4

5065

1.99B

78.60%

+584.81K

2023Q3

4871

1.98B

78.17%

-32.03M

2023Q2

4864

2.00B

78.94%

-18.54M

2023Q1

4818

1.99B

78.43%

-16.95M

2022Q4

4785

1.98B

77.94%

-5.23M

Ver Mais

Atividade dos Acionistas

Nome

Ações detidas

Proporção

Variação

Chg %

Data

The Vanguard Group, Inc.

253.26M

10.03%

+3.27M

+1.31%

Feb 28, 2025

BlackRock Institutional Trust Company, N.A.

143.39M

5.68%

+10.26M

+7.71%

Dec 31, 2024

State Street Global Advisors (US)

120.91M

4.79%

+1.88M

+1.58%

Dec 31, 2024

Wellington Management Company, LLP

80.74M

3.2%

+4.93M

+6.51%

Dec 31, 2024

Geode Capital Management, L.L.C.

61.18M

2.42%

+2.03M

+3.43%

Dec 31, 2024

Norges Bank Investment Management (NBIM)

34.98M

1.38%

+1.17M

+3.47%

Dec 31, 2024

Fidelity Management & Research Company LLC

33.58M

1.33%

-11.95M

-26.24%

Dec 31, 2024

BofA Global Research (US)

23.08M

0.91%

-1.38M

-5.65%

Dec 31, 2024

BlackRock Asset Management Ireland Limited

21.22M

0.84%

+1.34M

+6.77%

Dec 31, 2024

Morgan Stanley Smith Barney LLC

20.63M

0.82%

-290.99K

-1.39%

Dec 31, 2024

Ver Mais

ETFs Relacionados

Tempo de atualização: qua, 2 de abr

Nome

Proporção

FT Vest DJIA Dogs 10 Target Income ETF

11.99%

First Trust NASDAQ Pharmaceuticals ETF

6.57%

ProShares Pet Care ETF

5.23%

TBG Dividend Focus ETF

4.77%

Amplify Weight Loss Drug & Treatment ETF

4.76%

VanEck Pharmaceutical ETF

4.61%

Invesco Pharmaceuticals ETF

4.51%

Tema Oncology ETF

4.49%

ProShares Smart Materials ETF

4.3%

Proshares Ultra Health Care

4.3%

Ver Mais

FT Vest DJIA Dogs 10 Target Income ETF

Proporção11.99%

First Trust NASDAQ Pharmaceuticals ETF

Proporção6.57%

ProShares Pet Care ETF

Proporção5.23%

TBG Dividend Focus ETF

Proporção4.77%

Amplify Weight Loss Drug & Treatment ETF

Proporção4.76%

VanEck Pharmaceutical ETF

Proporção4.61%

Invesco Pharmaceuticals ETF

Proporção4.51%

Tema Oncology ETF

Proporção4.49%

ProShares Smart Materials ETF

Proporção4.3%

Proshares Ultra Health Care

Proporção4.3%

Dividendo

Um total de 35.12B USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro das ações

Data de pagamento

Data de ex-dividendo

Jan 28, 2025

MRK.NB Interim Cash Dividend of gross USD 0.81 paid on Apr 07, 2025 going ex on Mar 17, 2025

Mar 17, 2025

Apr 07, 2025

Mar 17, 2025

Nov 19, 2024

MRK.NB Final Cash Dividend of gross USD 0.81 paid on Jan 08, 2025 going ex on Dec 16, 2024

Dec 16, 2024

Jan 08, 2025

Dec 16, 2024

Jul 23, 2024

MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Oct 07, 2024 going ex on Sep 16, 2024

Sep 16, 2024

Oct 07, 2024

Sep 16, 2024

May 29, 2024

MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Jul 08, 2024 going ex on Jun 17, 2024

Jun 17, 2024

Jul 08, 2024

Jun 17, 2024

Jan 23, 2024

MRK.NB Interim Cash Dividend of gross USD 0.77 paid on Apr 05, 2024 going ex on Mar 14, 2024

Mar 15, 2024

Apr 05, 2024

Mar 14, 2024

Nov 28, 2023

MRK.NB Final Cash Dividend of gross USD 0.77 paid on Jan 08, 2024 going ex on Dec 14, 2023

Dec 15, 2023

Jan 08, 2024

Dec 14, 2023

Jul 25, 2023

MRK.NB Interim Cash Dividend of gross USD 0.73 paid on Oct 06, 2023 going ex on Sep 14, 2023

Sep 15, 2023

Oct 06, 2023

Sep 14, 2023

May 23, 2023

MRK.NB Interim Cash Dividend of gross USD 0.73 paid on Jul 10, 2023 going ex on Jun 14, 2023

Jun 15, 2023

Jul 10, 2023

Jun 14, 2023

Jan 24, 2023

MRK.NB Interim Cash Dividend of gross USD 0.73 paid on Apr 10, 2023 going ex on Mar 14, 2023

Mar 15, 2023

Apr 10, 2023

Mar 14, 2023

Nov 30, 2022

MRK.NB Final Cash Dividend of gross USD 0.73 paid on Jan 09, 2023 going ex on Dec 14, 2022

Dec 15, 2022

Jan 09, 2023

Dec 14, 2022

Ver Mais

Desdobramento de Ações

Data

Tipo

Proporção

Sem dados

Data

Tipo

Proporção

Sem dados

Merck & Co Inc

86.770USD

Merck & Co Inc

86.770

Visão Geral

Empresa